The company said Exalgo 32mg extended release
tablets (hydromorphone HCl) is an opioid agonist indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.
4 mg/dL for ViramuneEeA IR and 11 mg/dL for nevirapine extended release
formulation (ViramuneEeA XR)).
ANDAs are being submitted to obtain regulatory approval to market these extended release
versions, and this is resulting in some high profile patent infringement lawsuits.
SECUREL is an proprietary abuse deterrent extended release
technology for opioid drugs.
Wilds, President and CEO of SCOLR Pharma, said, "While we are disappointed that our initial work on an extended release
phenylepherine formulation does not support further commercial development, the successful completion of our second ondansetron study represents the achievement of another important milestone for our Company.
Upon US FDA approval, the extended release
formulation of lorcaserin will offer patients a chronic weight management treatment in a once-daily dosing option, added the company.
Statements in this press release about future expectations, plans and prospects for the Company, including the Company's expectations regarding implementation of its revised sales and marketing strategy and its current development plans for an extended release
formulation of BiDil, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
According to the company, Oxtellar XR is the first approved novel, oral, once-daily extended release
formulation of oxcarbazepine for the treatment of epilepsy.
announced today that Esprit has paid Depomed the $10 million license fee payment due under the parties' license agreement for ProQuin([R]) XR, the extended release
formulation of the antibiotic ciprofloxacin developed by Depomed and exclusively licensed in the United States to Esprit.
M2 EQUITYBITES-June 1, 2015-Ultragenyx commences Phase III study of aceneuramic acid extended release
s (AMEX: ELI) marketing partner, ECR Pharmaceuticals, has launched Elite's second once-a-day allergy product, under ECR's brand LODRANE 24D, an extended release
formulation of brompheniramine maleate and pseudoephedrine HCl.
M2 PHARMA-June 1, 2015-Ultragenyx commences Phase III study of aceneuramic acid extended release